London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada.
Lab Invest. 2010 Aug;90(8):1247-58. doi: 10.1038/labinvest.2010.97. Epub 2010 May 10.
Early breast cancer progression involves advancement through specific morphological stages including atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS) and invasive mammary carcinoma (IMC), although not necessarily always in a linear fashion. Observational studies have examined genetic, epigenetic and gene expression differences in breast tissues representing these stages of progression, but model systems which would allow for experimental testing of specific factors influencing transition through these stages are scarce. The 21T series cell lines, all originally derived from the same patient with metastatic breast cancer, have been proposed to represent a mammary tumor progression series. We report here that three of the 21T cell lines indeed mimic specific stages of human breast cancer progression (21PT-derived cells, ADH; 21NT-derived cells, DCIS; 21MT-1 cells, IMC) when grown in the mammary fat pad of nude mice, albeit after a year. To develop a more rapid, readily manipulatable in vitro assay for examining the biological differences between these cell lines, we have used a 3D Matrigel system. When the three cell lines were grown in 3D Matrigel, they showed characteristic morphologies, in which quantifiable aspects of stage-specific in vivo behaviors (ie, differences in acinar structure formation, cell polarization, colony morphology, cell proliferation, cell invasion) were recapitulated in a reproducible fashion. Gene expression profiling revealed a characteristic pattern for each of the three cell lines. Interestingly, Wnt pathway alterations are particularly predominant in the early transition from 21PTci (ADH) to 21NTci (DCIS), whereas alterations in expression of genes associated with control of cell motility and invasion phenomena are more prominent in the later transition of 21NTci (DCIS) to 21MT-1 (IMC). This system thus reveals potential therapeutic targets and will provide a means of testing the influences of identified genes on transitions between these stages of pre-malignant to malignant growth.
早期乳腺癌的进展涉及通过特定的形态学阶段的进展,包括非典型导管增生(ADH),导管原位癌(DCIS)和浸润性乳腺癌(IMC),尽管不一定总是以线性方式。观察性研究已经检查了代表这些进展阶段的乳腺组织中的遗传,表观遗传和基因表达差异,但允许对影响通过这些阶段的特定因素进行实验测试的模型系统却很少。21T 系列细胞系均最初源自同一转移性乳腺癌患者,据推测代表了乳腺肿瘤进展系列。我们在这里报告,当在裸鼠的乳腺脂肪垫中生长时,21T 细胞系中的三种确实模拟了人类乳腺癌进展的特定阶段(21PT 衍生细胞,ADH;21NT 衍生细胞,DCIS;21MT-1 细胞,IMC),尽管需要一年的时间。为了开发一种更快速,易于操作的体外测定法来检查这些细胞系之间的生物学差异,我们使用了 3D Matrigel 系统。当将三种细胞系在 3D Matrigel 中生长时,它们表现出特征性形态,其中可量化的体内行为(即,腺泡结构形成,细胞极化,菌落形态,细胞增殖,细胞侵袭)的特定阶段差异以可重复的方式再现。基因表达谱分析揭示了三种细胞系各自的特征模式。有趣的是,Wnt 通路改变在从 21PTci(ADH)到 21NTci(DCIS)的早期转变中特别突出,而与控制细胞迁移和侵袭现象的基因表达改变在 21NTci(DCIS)向 21MT-1(IMC)的晚期转变中更为突出。该系统因此揭示了潜在的治疗靶标,并将提供一种测试已鉴定基因对这些前恶性至恶性生长阶段之间转变的影响的方法。